Description

Introduction Gliflozins inhibit renal glucose reabsorption by blocking the SGLT2 cotransporters in the proximal renal tubules and causing glucosuria. This reduces glycemia and lowers HbA1c by ~1.0%.SGLT2 inhibitors are a class of prescription medicines that are FDA-approved for use with diet and exercise to lower blood sugar in adults with type II diabetes. Medicines in the SGLT2 inhibitor class include canagliflozin, dapagliflozin, and empagliflozin.This class of drugs block SGLT-2 protein from the site of the proximal convoluted tubule (PCT) in the kidney, resulting in prevent reabsorption of a glucose molecule and allow excretion of glucose molecule through urine. SGLT-2 inhibitors